Bioventus Inc (OQ:BVS)

May 07, 2024 07:00 am ET
Bioventus Reports First Quarter Financial Results
Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three months ended March 30, 2024. “We are pleased with the strong start to the year driven by...
Apr 29, 2024 07:30 am ET
Bioventus to Report First Quarter of Fiscal Year 2024 Financial Results on May 7, 2024
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2024 before the market opens on Tuesday, May...
Mar 12, 2024 07:30 am ET
Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced fourth quarter and full-year financial results for the year ended December 31, 2023, and provided its financial guidance...
Mar 04, 2024 08:00 am ET
Bioventus to Report Fourth Quarter of Fiscal Year 2023 Financial Results on March 12, 2024
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2024 before the market opens on Tuesday,...
Feb 14, 2024 08:01 am ET
INVESTIGATION ALERT: Kaskela Law LLC Announces Shareholder Investigation of Bioventus Inc. (NASDAQ: BVS) and Encourages Long-Term Investors to Contact the Firm
Kaskela Law LLC announces that it has commenced an investigation into Bioventus Inc. (NASDAQ: BVS) (“Bioventus”) on behalf of the company’s long-term investors. Recently an amended securities fraud complaint was filed against Bioventus on behalf...
Feb 12, 2024 09:00 pm ET
BIOVENTUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Bioventus Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Bioventus Inc. (NASDAQ: BVS) on behalf of long-term stockholders following a class action complaint that was filed against...
Jan 18, 2024 04:15 pm ET
Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it has entered into an Amendment No. 5 (the “Amendment”) to the Credit and Guaranty Agreement, between the Company,...
Jan 12, 2024 04:15 pm ET
Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today the issuance on January 11, 2024 of previously disclosed inducement equity awards to Robert (Rob) Claypoole in...
Dec 26, 2023 09:00 pm ET
BIOVENTUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Bioventus Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Bioventus Inc. (NASDAQ: BVS) on behalf of long-term stockholders following a class action complaint that was filed against Bioventus on January 12, 2023 with a Class Period Pursuant to the February 11, 2021 IPO. Our investigation concerns whether the board of directors of Bioventus have breached their fiduciary duties to the company.
Dec 19, 2023 04:30 pm ET
Bioventus Names Robert Claypoole as President and Chief Executive Officer
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that its Board of Directors has appointed Robert (Rob) Claypoole as Bioventus’ President and Chief Executive Officer and...
Dec 06, 2023 08:00 am ET
Bioventus Agrees to Nationwide Contract with Aetna™ Medicare Advantage Plans for DUROLANE® for Knee Osteoarthritis
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has agreed to a nationwide contract with Aetna™ Medicare Advantage plans. Beginning January 1, 2024, over 3 million Aetna™ Medicare...
Nov 07, 2023 07:00 am ET
Bioventus Reports Third Quarter Financial Results; Raises Full Year 2023 Financial Guidance
Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the three and nine months ended September 30, 2023....
Oct 31, 2023 07:00 am ET
Bioventus to Report Third Quarter of Fiscal Year 2023 Financial Results on November 7, 2023
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2023 before the market opens on Tuesday,...
Sep 19, 2023 09:52 pm ET
Bioventus to Present at the Cantor Global Healthcare Conference
Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, senior vice president and chief financial officer, will participate in a fireside chat at the Cantor Global Healthcare Conference...
Sep 06, 2023 04:30 pm ET
Bioventus to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Tony Bihl, interim chief executive officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Wednesday,...
Aug 08, 2023 07:30 am ET
Bioventus Reports Second Quarter Financial Results; Introduces Full Year 2023 Financial Guidance
Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the three and six months ended July 1, 2023. Q2 Financial Summary: Net Sales of...
Aug 04, 2023 08:30 am ET
Bioventus to Present at the Canaccord Genuity 43rd Annual Global Growth Conference
Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, senior vice president and chief financial officer, will present at the Canaccord Genuity Global Growth Conference on Thursday,...
Aug 01, 2023 05:35 pm ET
Bioventus to Report Second Quarter of Fiscal Year 2023 Financial Results on August 8, 2023
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2023 before the market opens on Tuesday,...
May 23, 2023 07:30 am ET
Bioventus Completes Divestiture of its Wound Business
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has successfully completed the divestiture of its Wound business, including the skin substitutes TheraSkin and...
May 16, 2023 04:15 pm ET
Bioventus Reports First Quarter Financial Results
Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the three months ended April 1, 2023. Q1 Financial Summary: Net Sales of $119.1 million,...
May 15, 2023 05:33 pm ET
Bioventus Reschedules Reporting of First Quarter Fiscal Year 2023 Financial Results to After Market Close on May 16, 2023
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will now report financial results for the first quarter of fiscal year 2023 after the market closes on Tuesday,...
May 11, 2023 07:00 am ET
Bioventus Reschedules Earnings Call to May 16, 2023; Files for Extension to File Form 10-Q for the Period Ended April 1, 2023
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today the Company plans to file Form 12b-25, Notification of Late Filing, for its Quarterly Report on Form 10-Q for the period...
May 10, 2023 09:00 am ET
Bioventus Announces Divestiture of its Wound Business
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has signed a definitive agreement to sell its Wound business, including the skin substitutes TheraSkin and...
May 03, 2023 08:30 am ET
Bioventus to Report First Quarter of Fiscal Year 2023 Financial Results on May 11, 2023
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2023 before the market opens on Thursday, May...
Apr 05, 2023 08:00 am ET
Bioventus Announces CEO Leadership Change
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced that Ken M. Reali has stepped down as Chief Executive Officer (CEO) and as a member of the Board of Directors (board)....
Mar 31, 2023 07:30 am ET
Bioventus Reports Fourth Quarter and Full-Year 2022 Financial Results
Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the year ended December 31, 2022. Q4 Financial Summary & Recent Highlights: Net Sales of...
Mar 31, 2023 07:00 am ET
Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has entered into an Amendment No. 4 (the “Amendment”) to the Credit and Guaranty Agreement, between the Company,...
Mar 29, 2023 08:55 am ET
Bioventus Reschedules Reporting of Fourth Quarter Fiscal Year 2022 Financial Results to March 31, 2023
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will now report financial results for the fourth quarter of fiscal year 2022 before the market opens on Friday,...
Mar 16, 2023 08:30 am ET
Bioventus to Report Fourth Quarter of Fiscal Year 2022 Financial Results on March 30, 2023
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2022 before the market opens on Thursday,...
Mar 13, 2023 03:08 pm ET
SHAREHOLDER ALERT FILING DEADLINE TODAY: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bioventus Inc. of Class Action Lawsuit and Upcoming Deadline - BVS
NEW YORK, March 13, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS) and certain officers and directors. The class action, filed in the United States District Court for the Middle District of North Carolina, and docketed under 23-cv-00032, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Bioventus Class A common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with
Mar 13, 2023 12:24 pm ET
DEADLINE ALERT for GWH, BVS, YMAB, and FATE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Mar 13, 2023 11:00 am ET
Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Bioventus Inc. (BVS) Investors of Class Action and Last Few Hours to Actively Participate
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Bioventus Inc. (“Bioventus” or the “Company”) (NASDAQ: BVS) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired: (a) Bioventus Class A common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about February 11, 2021 (the "IPO" or "Offering"); and/or (b) Bioventus securities between February 11, 2021 and November 21
Mar 12, 2023 08:50 pm ET
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Bioventus Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 12, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Bioventus Inc. ("Bioventus" or "the Company") (NASDAQ:BVS) for violations of the federal securities laws.
Mar 11, 2023 01:41 pm ET
BVS MONDAY DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Bioventus Inc. Investors to Secure Counsel Before Important March 13 Deadline in Securities Class Action – BVS
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the stock of Bioventus Inc. (NASDAQ: BVS): (i) pursuant and/or traceable to the offering documents issued in connection with the Company’s February 11, 2021 initial...
Mar 11, 2023 06:00 am ET
BIOVENTUS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Bioventus To Contact Him Directly To Discuss The
NEW YORK, March 11, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS) and reminds investors of the March 13, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Mar 10, 2023 09:00 pm ET
BIOVENTUS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Bioventus Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Bioventus Inc. (“Bioventus” or the “Company”) (NASDAQ: BVS) in the United States District Court for the Middle District of North Carolina on behalf of all persons and entities who purchased or otherwise acquired Bioventus securities pursuant to the February 11, 2021 IPO, both dates inclusive (the “Class Period”). Investors have until March 13, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Mar 10, 2023 01:37 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bioventus Inc. of Class Action Lawsuit and Upcoming Deadline – BVS
Pomerantz LLP announces that a class action lawsuit has been filed against Bioventus Inc. (“Bioventus” or the “Company”) (NASDAQ: BVS) and certain officers and directors.   The class action, filed in the United States District Court for the Middle...
Mar 10, 2023 10:00 am ET
YMAB, BVS & FATE Class Action Reminders: Bronstein, Gewirtz & Grossman, LLC, A Successful Firm, Reminds Investors of Deadlines and to Actively Participate
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Mar 10, 2023 09:00 am ET
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Bioventus Inc. (BVS)
The Law Offices of Frank R. Cruz reminds investors of the upcoming March 13, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Bioventus Inc. (“Bioventus” or the “Company”) (NASDAQ:
Mar 09, 2023 08:05 pm ET
Bioventus Inc Investors: Please contact the Portnoy Law Firm to recover your losses
The Portnoy Law Firm advises Bioventus Inc (“Bioventus”) (NASDAQ: BVS) investors that the law firm has initiated an investigation on behalf of investors that lost money on their Bioventus stock. Bioventus investors are encouraged to contact the...
Mar 09, 2023 08:00 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Bioventus Inc. (BVS)
LOS ANGELES, March 9, 2023 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming March 13, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS) investors who purchased: (a) Class A common stock pursuant and or traceable to the Offering Documents issued in connection with the Company's February 2021 initial public offering ("IPO"); and/or (b) securities between February 11, 2021 and November 21, 2022, inclusive (the "Class Period").
Mar 07, 2023 12:00 pm ET
DEADLINE ALERT for BVS, GWH, YMAB, FATE: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Mar 06, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Southwest Airlines, Y-mAbs, Bioventus, and ESS and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Southwest Airlines Co. (NYSE: LUV), Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB),...
Mar 06, 2023 07:26 pm ET
Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Bioventus Inc. (BVS) Investors and Encourages Investors to Contact the Firm Before March 13, 2023
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Middle District of North Carolina on behalf of those who acquired Bioventus Inc. (“Bioventus” or the “Company”) (NASDAQ: BVS) securities during the period from February 11, 2021 through November 21,
Mar 06, 2023 11:50 am ET
DEADLINE ALERT for GWH, BVS, YMAB, and FATE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Mar 06, 2023 11:00 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Bioventus Inc. (BVS)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming March 13, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of Bioventus Inc. (“Bioventus” or the “Company”) (NASDAQ: BVS) investors who...
Mar 06, 2023 10:04 am ET
BVS DEADLINE NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Bioventus Inc. Investors with Losses to Secure Counsel Before Important March 13 Deadline in Securities Class Action – BVS
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the stock of Bioventus Inc. (NASDAQ: BVS): (i) pursuant and/or traceable to the offering documents issued in connection with the Company’s February 11, 2021 initial...
Mar 06, 2023 01:45 am ET
BIOVENTUS INC. (NASDAQ: BVS) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Biove
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or otherwise...
Mar 04, 2023 10:00 am ET
YMAB, BVS & FATE Class Action Reminders: Bronstein, Gewirtz & Grossman, LLC, A Successful Firm, Reminds Investors of Deadlines and to Actively Participate
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Mar 02, 2023 07:00 pm ET
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Bioventus Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 2, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Bioventus Inc. ("Bioventus" or "the Company") (NASDAQ:BVS) for violations of the federal securities la
Mar 01, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Y-mAbs, Bioventus, ESS, and IBM and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB), Bioventus Inc. (NASDAQ: BVS), ESS...
Mar 01, 2023 06:59 pm ET
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Bioventus Inc. Investors to Secure Counsel Before Important March 13 Deadline in Securities Class Action – BVS
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the stock of Bioventus Inc. (NASDAQ: BVS): (i) pursuant and/or traceable to the offering documents issued in connection with the Company’s February 11, 2021 initial...
Mar 01, 2023 01:42 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bioventus Inc. of Class Action Lawsuit and Upcoming Deadline – BVS
Pomerantz LLP announces that a class action lawsuit has been filed against Bioventus Inc. (“Bioventus” or the “Company”) (NASDAQ: BVS) and certain officers and directors. The class action, filed in the United States District Court for the Middle...
Mar 01, 2023 01:00 pm ET
DEADLINE ALERT for BVS, GWH, YMAB, FATE: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Feb 28, 2023 12:15 pm ET
DEADLINE ALERT for GWH, BVS, YMAB, and FATE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Feb 28, 2023 10:00 am ET
YMAB, BVS & FATE Class Action Reminders: Bronstein, Gewirtz & Grossman, LLC, A Successful Firm, Reminds Investors of Deadlines and to Actively Participate
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Feb 28, 2023 07:30 am ET
Bioventus Enters into Settlement Agreement to Preserve Maximum Optionality – Up To $350mm of Potential Liability Reduction and a Release of Future Claims related to the CartiHeal Acquisition
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has entered into a Settlement Agreement (the “Settlement Agreement”) with the former CartiHeal shareholders (the...
Feb 27, 2023 03:30 pm ET
BIOVENTUS INC. (NASDAQ: BVS) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Biove
Did you lose money on investments in Bioventus?  If so, please visit Bioventus Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
Feb 27, 2023 11:00 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Bioventus Inc. (BVS)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming March 13, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of Bioventus Inc. (“Bioventus” or the “Company”) (NASDAQ: BVS) investors who...
Feb 25, 2023 06:00 am ET
BIOVENTUS DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Bioventus To Contact Him Directly To Discuss Their Options
NEW YORK, Feb. 25, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS) and reminds investors of the March 13, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Feb 24, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Y-mAbs, Bioventus, ESS, and IBM and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB), Bioventus Inc. (NASDAQ: BVS), ESS...
Feb 24, 2023 04:13 pm ET
ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages Bioventus Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BVS
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the stock of Bioventus Inc. (NASDAQ: BVS): (i) pursuant and/or traceable to the offering documents issued in connection with the Company’s February 11, 2021 initial...
Feb 24, 2023 12:00 pm ET
BVS Investors Have Opportunity to Lead Bioventus Inc. Securities Fraud Lawsuit
LOS ANGELES, Feb. 24, 2023 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS).
Feb 23, 2023 06:54 pm ET
SHAREHOLDER UPDATE: Y-mAbs Therapeutics, Bioventus Inc, Fate Therapeutics, Inc, and Invivyd Inc: Johnson Fistel Encourages Shareholders to Seek Counsel for Class Action Lawsuits
Shareholder rights law firm Johnson Fistel, LLP announces that class action lawsuits have commenced on behalf of investors of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB), Bioventus Inc. (NASDAQ: BVS), and Fate Therapeutics, Inc. (NASDAQ: FATE), and...
Feb 23, 2023 11:00 am ET
DEADLINE ALERT for BVS, GWH, YMAB, FATE: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Feb 22, 2023 11:49 am ET
DEADLINE ALERT for GWH, BVS, YMAB, and FATE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Feb 22, 2023 10:00 am ET
YMAB, BVS & FATE Class Action Reminders: Bronstein, Gewirtz & Grossman, LLC, A Successful Firm, Reminds Investors of Deadlines and to Actively Participate
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Feb 20, 2023 06:12 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bioventus Inc. of Class Action Lawsuit and Upcoming Deadline – BVS
Pomerantz LLP announces that a class action lawsuit has been filed against Bioventus Inc. (“Bioventus” or the “Company”) (NASDAQ: BVS) and certain officers and directors. The class action, filed in the United States District Court for the Middle...
Feb 19, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Southwest Airlines, Y-mAbs, Bioventus, and ESS and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Southwest Airlines Co. (NYSE: LUV), Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB),...
Feb 19, 2023 11:55 am ET
ROSEN, LEADING INVESTOR COUNSEL, Encourages Bioventus Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – BVS
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the stock of Bioventus Inc. (NASDAQ: BVS): (i) pursuant and/or traceable to the offering documents issued in connection with the Company’s February 11, 2021 initial...
Feb 18, 2023 06:00 am ET
BIOVENTUS DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Bioventus To Contact Him Directly To Discuss Their Options
NEW YORK, Feb. 18, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS) and reminds investors of the March 13, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Feb 16, 2023 10:00 am ET
DEADLINE ALERT for BVS, GWH, YMAB, FATE: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Feb 16, 2023 10:00 am ET
YMAB, BVS & FATE Class Action Reminders: Bronstein, Gewirtz & Grossman, LLC, A Successful Firm, Reminds Investors of Deadlines and to Actively Participate
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Feb 14, 2023 05:41 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bioventus Inc. of Class Action Lawsuit and Upcoming Deadline – BVS
Pomerantz LLP announces that a class action lawsuit has been filed against Bioventus Inc. (“Bioventus” or the “Company”) (NASDAQ: BVS) and certain officers and directors.   The class action, filed in the United States District Court for the Middle...
Feb 14, 2023 12:45 pm ET
DEADLINE ALERT for GWH, BVS, YMAB, and FATE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Feb 14, 2023 12:00 pm ET
Bioventus Inc Investors: Please contact the Portnoy Law Firm to recover your losses
The Portnoy Law Firm advises Bioventus Inc (“Bioventus”) (NASDAQ: BVS) investors that the law firm has initiated an investigation on behalf of investors that lost money on their Bioventus stock. Bioventus investors are encouraged to contact the...
Feb 14, 2023 11:00 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Bioventus Inc. (BVS)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming March 13, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of Bioventus Inc. (“Bioventus” or the “Company”) (NASDAQ: BVS) investors who...
Feb 14, 2023 01:45 am ET
BIOVENTUS INC. (NASDAQ: BVS) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Biove
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or otherwise...
Feb 13, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Y-mAbs, Bioventus, ESS, and IBM and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB), Bioventus Inc. (NASDAQ: BVS), ESS...
Feb 13, 2023 06:15 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bioventus Inc. of Class Action Lawsuit and Upcoming Deadline - BVS
NEW YORK, Feb. 13, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS) and certain officers and directors.  The class action, filed in the United States District Court for the Middle District of North Carolina, and docketed under 23-cv-00032, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Bioventus Class A common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with
Feb 09, 2023 05:40 pm ET
Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Bioventus Inc. (BVS) Investors and Encourages Investors to Contact the Firm Before March 13, 2023
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Middle District of North Carolina on behalf of those who acquired Bioventus Inc. (“Bioventus” or the “Company”) (NASDAQ:...
Feb 09, 2023 11:00 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Bioventus Inc. (BVS)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming March 13, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of Bioventus Inc. (“Bioventus” or the “Company”) (NASDAQ: BVS) investors who...
Feb 09, 2023 10:00 am ET
YMAB, BVS & FATE Class Action Reminders: Bronstein, Gewirtz & Grossman, LLC, A Successful Firm, Reminds Investors of Deadlines and to Actively Participate
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Feb 08, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bioventus, ESS, IBM, and FATE and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Bioventus Inc. (NASDAQ: BVS), ESS Tech, Inc. (NYSE: GWH, GWH.WT), International...
Feb 08, 2023 03:50 pm ET
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Bioventus Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – BVS
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the stock of Bioventus Inc. (NASDAQ: BVS): (i) pursuant and/or traceable to the offering documents issued in connection with the Company’s February 11, 2021 initial...
Feb 08, 2023 12:15 pm ET
DEADLINE ALERT for LUV, GWH, BVS, and YMAB: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Feb 08, 2023 12:00 pm ET
BVS Investors Have Opportunity to Lead Bioventus Inc. Securities Fraud Lawsuit
LOS ANGELES, Feb. 8, 2023 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS).
Feb 08, 2023 11:30 am ET
BIOVENTUS INC. (NASDAQ: BVS) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Biove
Did you lose money on investments in Bioventus?  If so, please visit Bioventus Inc. Shareholder Class Action Lawsuit or contact Joseph R. Seidman, Jr. at (877) 779-1414 or [email protected] to discuss your rights.                                                                                      
Feb 07, 2023 12:00 pm ET
DEADLINE ALERT for BVS, GWH, YMAB, FATE: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Feb 07, 2023 10:56 am ET
Class Action Deadlines: Y-mAbs Therapeutics, Bioventus Inc, Fate Therapeutics, Inc, and Invivyd Inc – Contact Johnson Fistel
Shareholder rights law firm Johnson Fistel, LLP announces that class action lawsuits have commenced on behalf of investors of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB), Bioventus Inc. (NASDAQ: BVS), and Fate Therapeutics, Inc. (NASDAQ: FATE), and...
Feb 07, 2023 01:45 am ET
BIOVENTUS INC. (NASDAQ: BVS) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Biove
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or otherwise...
Feb 06, 2023 11:10 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bioventus Inc. of Class Action Lawsuit and Upcoming Deadline - BVS
NEW YORK, Feb. 7, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS) and certain officers and directors.  The class action, filed in the United States District Court for the Middle District of North Carolina, and docketed under 23-cv-00032, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Bioventus Class A common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with
Feb 04, 2023 06:00 am ET
BIOVENTUS SHAREHOLDER NOTICE: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Bioventus To Contact Him Directly To Discuss Their Option
NEW YORK, Feb. 4, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS) and reminds investors of the March 13, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Feb 03, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bioventus, ESS, IBM, and FATE and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Bioventus Inc. (NASDAQ: BVS), ESS Tech, Inc. (NYSE: GWH, GWH.WT), International...
Feb 03, 2023 12:00 pm ET
BVS Investors Have Opportunity to Lead Bioventus Inc. Securities Fraud Lawsuit
LOS ANGELES, Feb. 3, 2023 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS).
Feb 02, 2023 12:11 pm ET
DEADLINE ALERT for LUV, GWH, BVS, and YMAB: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Feb 02, 2023 10:37 am ET
YMAB, BVS & FATE Class Action Reminders: Bronstein, Gewirtz & Grossman, LLC, A Successful Firm, Reminds Investors of Deadlines and to Actively Participate
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Feb 01, 2023 11:00 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Bioventus Inc. (BVS)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming March 13, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of Bioventus Inc. (“Bioventus” or the “Company”) (NASDAQ: BVS) investors who...
Feb 01, 2023 12:45 am ET
BIOVENTUS INC. (NASDAQ: BVS) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Biove
Did you lose money on investments in Bioventus?  If so, please visit Bioventus Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.                                                                                      
Jan 31, 2023 02:43 pm ET
DEADLINE ALERT for BVS, GWH, YMAB, FATE: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Jan 31, 2023 01:45 am ET
BIOVENTUS INC. (NASDAQ: BVS) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Biove
BIOVENTUS INC. (NASDAQ: BVS) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Bioventus Inc. (NASDAQ: BVS) Did you lose money on...
Jan 30, 2023 11:00 am ET
Bronstein, Gewirtz & Grossman, LLC Notifies Bioventus Inc. (BVS) Investors of Class Action and to Actively Participate
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Bioventus Inc. (“Bioventus” or the “Company”) (NASDAQ: BVS) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired: (a) Bioventus Class A common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about February 11, 2021 (the "IPO" or "Offering"); and/or (b) Bioventus securities between February 11, 2021 and November 21
Jan 29, 2023 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bioventus, ESS, and IBM and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Bioventus Inc. (NASDAQ: BVS), ESS Tech, Inc. (NYSE: GWH, GWH.WT), and...
Jan 29, 2023 02:13 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bioventus Inc. of Class Action Lawsuit and Upcoming Deadline – BVS
Pomerantz LLP announces that a class action lawsuit has been filed against Bioventus Inc. (“Bioventus” or the “Company”) (NASDAQ: BVS) and certain officers and directors.   The class action, filed in the United States District Court for the Middle...
Jan 28, 2023 05:43 am ET
BIOVENTUS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Bioventus To Contact Him Directly To Discuss The
NEW YORK, Jan. 28, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS) and reminds investors of the March 13, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Jan 27, 2023 06:46 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bioventus Inc. of Class Action Lawsuit and Upcoming Deadline - BVS
NEW YORK, Jan. 27, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS) and certain officers and directors. The class action, filed in the United States District Court for the Middle District of North Carolina, and docketed under 23-cv-00032, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Bioventus Class A common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with
Jan 27, 2023 02:47 pm ET
DEADLINE ALERT for LUV, GWH, and BVS: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Jan 27, 2023 12:37 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Bioventus Inc. (BVS)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming March 13, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of Bioventus Inc. (“Bioventus” or the “Company”) (NASDAQ:
Jan 26, 2023 06:25 pm ET
Bioventus Inc Investors: Please contact the Portnoy Law Firm to recover your losses
The Portnoy Law Firm advises Bioventus Inc (“Bioventus”) (NASDAQ: BVS) investors that the law firm has initiated an investigation on behalf of investors that lost money on their Bioventus stock. Bioventus investors are encouraged to contact the...
Jan 26, 2023 11:00 am ET
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Bioventus Inc. (BVS)
Law Offices of Howard G. Smith reminds investors of the upcoming March 13, 2023 deadline to file a lead plaintiff motion in the case filed on behalf of Bioventus Inc. (“Bioventus” or the “Company”) (NASDAQ: BVS) investors who purchased: (a) Class A common stock pursuant and or traceable to the Offering Documents issued in connection with the C
Jan 25, 2023 03:05 pm ET
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Bioventus Inc. (BVS) Investors
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Bioventus Inc. (“Bioventus” or the “Company”) (NASDAQ:
Jan 25, 2023 12:00 pm ET
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Bioventus Inc. (BVS) Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of Bioventus Inc. (“Bioventus” or the “Company”) (NASDAQ:
Jan 25, 2023 11:30 am ET
BIOVENTUS INC. (NASDAQ: BVS) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Bioventus Inc. (NASDAQ: BVS)
Did you lose money on investments in Bioventus? If so, please visit Bioventus Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
Jan 25, 2023 10:02 am ET
Lowey Dannenberg Notifies Bioventus Inc. (NASDAQ: BVS) Investors of Securities Class Action Lawsuit and Upcoming Lead Plaintiff Deadline
Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Bioventus Inc. (“Bioventus” or the “Company”) for violations of the federal securities laws on...
Jan 24, 2023 06:46 pm ET
EQUITY ALERT: ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Bioventus Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – B
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the stock of Bioventus Inc. (NASDAQ: BVS): (i) pursuant and/or traceable to the offering documents issued in connection with the Company’s February 11, 2021 initial public offering (the “IPO” or “Offering”); and/or (ii) between February 11, 2021 and November 21, 2022, both dates inclusive (the “Class Period”). If you wish to serve as lead plaintiff, you must move the Court no later than March 13, 2023.
Jan 24, 2023 06:28 pm ET
Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Bioventus Inc. (BVS) Investors and Encourages Investors to Contact the Firm Before March 13, 2023
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Middle District of North Carolina on behalf of those who acquired Bioventus Inc. (“Bioventus” or the “Company”) (NASDAQ:...
Jan 24, 2023 04:30 pm ET
BIOVENTUS INC. (NASDAQ: BVS) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Bioventus Inc. (NASDAQ: BVS)
Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired: (a) Bioventus Inc. (“Bioventus”) Class A common stock pursuant and/or traceable to the Offering...
Jan 24, 2023 01:45 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Bioventus Inc. (BVS) Investors
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of Bioventus Inc. (“Bioventus” or the “Company”) (NASDAQ: BVS) investors who purchased: (a) Class A common stock pursuant and or traceable to the Offering Documents issued in connection with the Company’s February 2021 initial public offering (“IPO”); and/or
Jan 23, 2023 09:00 pm ET
BIOVENTUS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Bioventus Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Bioventus Inc. (“Bioventus” or the “Company”) (NASDAQ: BVS) in the United States District Court for the Middle District of North Carolina on behalf of all persons and entities who purchased or otherwise acquired Bioventus securities pursuant to the February 11, 2021 IPO, both dates inclusive (the “Class Period”). Investors have until March 13, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Jan 23, 2023 04:52 pm ET
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf Bioventus Inc. (BVS) Investors
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Middle District of North Carolina on behalf of those who acquired Bioventus Inc. (“Bioventus” or the “Company”) (NASDAQ: BVS) securities during the period from February 11, 2021 through November 21,
Jan 23, 2023 09:00 am ET
Bronstein, Gewirtz & Grossman, LLC Notifies Bioventus Inc. (BVS) Investors of Class Action and to Actively Participate
NEW YORK, Jan. 23, 2023 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired: (a) Bioventus Class A common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about February 11, 2021 (the "IPO" or "Offering"); and/or (b) Bioventus secu
Jan 22, 2023 07:43 am ET
BIOVENTUS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Bioventus To Contact Him Directly To Discuss Thei
NEW YORK, Jan. 22, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS).
Jan 21, 2023 02:26 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bioventus Inc. of Class Action Lawsuit and Upcoming Deadline – BVS
Pomerantz LLP announces that a class action lawsuit has been filed against Bioventus Inc. (“Bioventus” or the “Company”) (NASDAQ: BVS) and certain officers and directors.   The class action, filed in the United States District Court for the Middle...
Jan 20, 2023 10:18 am ET
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Bioventus Inc. with Losses of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Bioventus Inc. (“Bioventus” or “the Company”) (NASDAQ:
Jan 19, 2023 10:31 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bioventus Inc. of Class Action Lawsuit and Upcoming Deadline - BVS
NEW YORK, Jan. 19, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS) and certain officers and directors. The class action, filed in the United States District Court for the Middle District of North Carolina, and docketed under 23-cv-00032, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Bioventus Class A common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with
Jan 19, 2023 10:25 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bioventus Inc. of Class Action Lawsuit and Upcoming Deadline - BVS
NEW YORK, Jan. 19, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS) and certain officers and directors.  The class action, filed in the United States District Court for the Middle District of North Carolina, and docketed under 23-cv-00032, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Bioventus Class A common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with
Jan 19, 2023 03:04 pm ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Bioventus Inc. with Losses of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Bioventus Inc. (“Bioventus” or “the Company”) (NASDAQ:
Jan 18, 2023 07:16 pm ET
BIOVENTUS INC. INVESTOR ALERT: Kaplan Fox & Kilshiemer LLP Notifies Bioventus Investors of a Class Action Lawsuit and Upcoming Deadline
Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Bioventus Inc. (“Bioventus” or the “Company”) (NASDAQ: BVS). A complaint has been filed on behalf of investors who purchased or otherwise acquired...
Jan 15, 2023 07:43 am ET
BIOVENTUS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Bioventus To Contact Him Directly To Discuss Thei
NEW YORK, Jan. 15, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS).
Jan 12, 2023 07:58 pm ET
Pomerantz Law Firm Announces the Filing of a Class Action Against Bioventus Inc. and Certain Officers and Directors - BVS
NEW YORK, Jan. 12, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS) and certain officers and directors. The class action, filed in the United States District Court for the Middle District of North Carolina, and docketed under 23-cv-00032, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Bioventus Class A common stock pursuant and/or traceable to the Offering Documents (defined below) issued in connection with
Jan 08, 2023 07:43 am ET
BIOVENTUS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Bioventus To Contact Him Directly To Discuss Thei
NEW YORK, Jan. 8, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS).
Jan 05, 2023 08:27 am ET
G-III Apparel, Bioventus, Beyond Meat, Invivyd Shareholder Update: Johnson Fistel Encourages Shareholders with Losses to Contact the Firm Regarding Class Action Investigation
Shareholder rights law firm Johnson Fistel, LLP is investigating G-III Apparel Group Ltd. (NASDAQ: GIII), Bioventus Inc. (NASDAQ: BVS), Beyond Meat Inc. (NASDAQ: BYND), Invivyd, Inc. (“Invivyd ” or the “Company”) (NASDAQ: IVVD) (Formerly named...
Jan 04, 2023 07:00 am ET
Bioventus to Present at the 41st Annual J.P. Morgan Healthcare Conference
Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Ken Reali, chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 5:15 p.m....
Dec 26, 2022 09:00 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bioventus Inc. - BVS
NEW YORK, Dec. 26, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS).  Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
Dec 13, 2022 02:27 pm ET
BIOVENTUS SHAREHOLDER ACTION REMINDER
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Bioventus To Contact Him Directly To Discuss Their Options
Dec 12, 2022 10:33 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bioventus Inc. - BVS
NEW YORK, Dec. 12, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS).  Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
Dec 07, 2022 09:16 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bioventus Inc. - BVS
Pomerantz LLP is investigating claims on behalf of investors of Bioventus Inc. (“Bioventus” or the “Company”) (NASDAQ: BVS). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Dec 07, 2022 03:46 pm ET
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Bioventus Inc. (BVS)
NEW YORK, Dec. 7, 2022 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS). Investors who purchased Bioventus securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/bvs.
Dec 06, 2022 04:42 pm ET
BIOVENTUS SHAREHOLDER ACTION REMINDER
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Bioventus To Contact Him Directly To Discuss Their Options
Dec 05, 2022 06:49 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bioventus Inc. - BVS
NEW YORK, Dec. 5, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Nov 29, 2022 01:00 pm ET
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Bioventus Inc. (BVS) on Behalf of Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Bioventus Inc. (“Bioventus” or the “Company”) (NASDAQ:
Nov 29, 2022 10:00 am ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Bioventus Inc. (BVS) on Behalf of Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Bioventus Inc. (“Bioventus” or the “Company”) (NASDAQ: BVS) investors concerning the Company’s possible violations of federal securities laws.
Nov 28, 2022 07:21 pm ET
The Law Offices of Frank R. Cruz Announces Investigation of Bioventus Inc. (BVS) on Behalf of Investors
The Law Offices of Frank R. Cruz announces an investigation of Bioventus Inc. (“Bioventus” or the “Company”) (NASDAQ:
Nov 28, 2022 06:02 pm ET
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Bioventus Inc. Investors to Inquire About Securities Class Action Investigation – BVS
WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Bioventus Inc. (NASDAQ: BVS) resulting from allegations that Bioventus may have issued materially misleading business information to the investing public.
Nov 28, 2022 05:32 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bioventus Inc. - BVS
Pomerantz LLP is investigating claims on behalf of investors of Bioventus Inc. (“Bioventus” or the “Company”) (NASDAQ: BVS). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Nov 28, 2022 04:31 pm ET
Bioventus Inc Investors: Please contact the Portnoy Law Firm to recover your losses
The Portnoy Law Firm advises Bioventus Inc (“Bioventus”) (NASDAQ: BVS) investors that the law firm has initiated an investigation on behalf of investors that lost money on their Bioventus stock. Bioventus investors are encouraged to contact the...
Nov 23, 2022 05:05 pm ET
Bioventus Inc. Shareholder Alert: Kaplan Fox Investigates Potential Securities Fraud (BVS)
Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Bioventus Inc. (“Bioventus”) (NASDAQ: BVS). If you would like to discuss our investigation, please contact us by emailing [email protected] or...
Nov 21, 2022 10:37 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bioventus Inc. - BVS
NEW YORK, Nov. 21, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Nov 21, 2022 05:15 pm ET
Bioventus Issues Revised Third Quarter Results; Updates Full-Year 2022 Financial Guidance
Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today amended its previously announced financial results for the three and nine months ended October 1, 2022. Due to the adverse...
Nov 21, 2022 08:48 am ET
Bioventus Inc. Shareholder News: Johnson Fistel Encourages BVS Shareholders with Losses to Contact the Firm Regarding Class Action Investigation
Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS), any of its executive officers, or others violated securities laws by misrepresenting or...
Nov 18, 2022 05:50 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bioventus Inc. - BVS
Pomerantz LLP is investigating claims on behalf of investors of Bioventus Inc. (“Bioventus” or the “Company”) (NASDAQ: BVS).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980. The...
Nov 17, 2022 07:46 pm ET
Bioventus Inc Investors: Please contact the Portnoy Law Firm to recover your losses
The Portnoy Law Firm advises Bioventus Inc (“Bioventus”) (NASDAQ: BVS) investors that the law firm has initiated an investigation on behalf of investors that lost money on their Bioventus stock. Bioventus investors are encouraged to contact the...
Nov 17, 2022 04:52 pm ET
Bioventus Inc. Investor Alert: Kaplan Fox Investigates Potential Securities Fraud (BVS)
Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Bioventus Inc. (“Bioventus”) (NASDAQ: BVS). If you would like to discuss our investigation, please contact us by emailing [email protected] or...
Nov 16, 2022 05:15 pm ET
Bioventus Files for Extension to File Form 10-Q for the Period Ended October 1, 2022
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today the Company has filed a Form 12b-25, Notification of Late Filing for its Quarterly Report on Form 10-Q for the period...
Nov 10, 2022 09:36 am ET
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Bioventus Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Bioventus Inc. (“Bioventus” or “the Company”) (NASDAQ:
Nov 09, 2022 03:26 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Bioventus Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Bioventus Inc. (“Bioventus” or “the Company”) (NASDAQ:
Nov 08, 2022 03:00 pm ET
Bioventus Inc. Shareholder News: Johnson Fistel Encourages BVS Shareholders with Losses to Contact the Firm Regarding Investigation
Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether Bioventus Inc. ("Bioventus" or the "Company") (NASDAQ: BVS), any of its executive officers, or others violated securities laws by misrepresenting or...
Nov 08, 2022 07:30 am ET
Bioventus Reports Third Quarter Results; Updates Full-Year 2022 Financial Guidance
Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the three and nine months ended October 1, 2022. Q3 Financial Summary & Recent Highlights:...
Oct 31, 2022 07:00 am ET
Bioventus to Report Third Quarter of Fiscal Year 2022 Financial Results on November 8, 2022
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2022 before the market opens on Tuesday,...
Oct 12, 2022 08:00 am ET
Bioventus to Showcase Full Orthobiologics and Ultrasonic Portfolio at NASS in Chicago   
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, will present its spine procedural solutions portfolio at the North American Spine Society (NASS) meeting in Chicago, October 12 through...
Aug 30, 2022 08:00 am ET
Bioventus to Present at the Morgan Stanley Global Healthcare Conference
Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, senior vice-president and chief financial officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare...
Aug 11, 2022 07:00 am ET
Bioventus Reports Second Quarter Results; Updates Full-Year 2022 Financial Guidance
Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the three and six months ended July 2, 2022. Q2 Financial Summary & Recent Highlights: Net Sales...
Aug 03, 2022 07:00 am ET
Bioventus Receives FDA 510(k) Clearance for SonaStar Elite  
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced the US Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s neXus® SonaStar Elite® handpiece....
Jul 26, 2022 07:00 am ET
Bioventus to Report Second Quarter of Fiscal Year 2022 Financial Results on August 11, 2022
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2022 before the market opens on Thursday,...
Jul 12, 2022 08:30 am ET
Bioventus Completes CartiHeal Acquisition
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has completed its acquisition of CartiHeal. “We are excited to add CartiHeal to our diverse portfolio of...
Jun 21, 2022 07:30 am ET
Bioventus Amends CartiHeal Acquisition Structure
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has entered into an amendment to the Option and Equity Purchase Agreement for its pending acquisition of...
May 10, 2022 07:00 am ET
Bioventus Reports First Quarter Results; Reaffirms Full-Year 2022 Financial Guidance
Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for three months ended April 2, 2022. Q1 Financial Summary & Recent Highlights:...
May 03, 2022 05:47 pm ET
Bioventus Cancels Proposed $415 Million Offering of Senior Notes; Reaffirms Full-Year 2022 Financial Guidance
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that its subsidiary, Bioventus LLC, has withdrawn its offering of senior notes that was announced on Tuesday, April 26,...
May 02, 2022 07:00 am ET
Bioventus Agrees to Nationwide Contract with Cigna Commercial Plans for DUROLANE® and GELSYN-3® for Knee Osteoarthritis
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has agreed to a nationwide contract with Cigna® commercial plans. Beginning July 1, 2022, Cigna® commercial plan members will have...
Apr 26, 2022 09:05 am ET
Bioventus Announces Preliminary First Quarter Net Sales and Adjusted EBITDA
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today preliminary financial results for the first quarter ended April 2, 2022. Preliminary First Quarter Net Sales and...
Apr 26, 2022 08:38 am ET
Bioventus Announces $415 Million Offering of Senior Notes
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that, subject to market conditions, its subsidiary Bioventus LLC (the “Issuer”) intends to offer for sale $415 million...
Apr 25, 2022 07:00 am ET
Bioventus to Report First Quarter of Fiscal Year 2022 Financial Results on May 10, 2022
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2022 before the market opens on Tuesday, May...
Apr 08, 2022 09:15 am ET
Bioventus TheraSkin Coverage Expands to Provide for 17 Million More Covered Lives
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that TheraSkin coverage now includes three out of the four largest commercial plans in the U.S. along with Medicare and...
Apr 05, 2022 07:00 am ET
Bioventus Announces Inducement Equity to SVP Chief Financial Officer Mark Singleton
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today the issuance on April 4, 2022 of previously disclosed inducement equity awards to Mark Singleton in connection with this...
Apr 04, 2022 07:00 am ET
Bioventus Exercises Call Option to Acquire CartiHeal
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it has exercised its call option to acquire CartiHeal Ltd., excluding the ownership interest already owned by...
Mar 16, 2022 07:00 am ET
Bioventus to Present at the Canaccord Genuity Musculoskeletal Conference
Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Ken Reali, chief executive officer, will participate in a fireside chat at the Canaccord Genuity Musculoskeletal Conference on Tuesday, March 22,...
Mar 10, 2022 07:00 am ET
Bioventus Reports Fourth Quarter and Full Year 2021 Financial Results; Introduces Full Year 2022 Financial Guidance
Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the fourth quarter and full-year ended December 31, 2021. Fourth Quarter Financial Summary &...
Mar 01, 2022 07:00 am ET
Bioventus Receives 510(k) Clearance for StimRouter Pain Management Device
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced that the US Food and Drug Administration (FDA) has awarded 510(k) clearance to the next generation StimRouter® Neuromodulation...
Feb 28, 2022 07:00 am ET
Bioventus Appoints Mark Singleton as Chief Financial Officer
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it has appointed Mark Singleton as the Company’s Senior Vice President, Chief Financial Officer and Principal...
Feb 22, 2022 07:00 am ET
Bioventus to Report Fourth Quarter and Fiscal Year 2021 Financial Results on March 10, 2022
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter and fiscal year 2021 before the market opens on Thursday,...
Feb 09, 2022 06:35 am ET
SWK Holdings Provides Portfolio Update Highlighting Recent Achievements
DALLAS, Feb. 9, 2022 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today provided an update on the progress and achievements of its portfolio and partner companies during the second half of 2021 and recent weeks.
Jan 11, 2022 07:00 am ET
Bioventus Announces Preliminary Fourth Quarter and Full-Year 2021 Revenue
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today preliminary revenue results for the fourth quarter and full-year 2021. Preliminary, unaudited revenue for the fourth...
Dec 28, 2021 07:00 am ET
Bioventus to Present at the 40th Annual J.P. Morgan Healthcare Conference
Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Ken Reali, chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference via webcast on Wednesday, January 12, 2022,...
Dec 21, 2021 09:25 am ET
Bioventus Appoints Michelle McMurry-Heath to Board of Directors
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has announced the appointment of Michelle McMurry-Heath, MD, PhD, to the Company’s Board of Directors, effective January 1, 2022. Over...
Dec 20, 2021 08:30 am ET
Bioventus Receives US FDA Clearance for BoneScalpel® Access™
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced the US Food and Drug Administration (FDA) has granted 510(k) clearance for the Company’s neXus® BoneScalpel® Access™...
Nov 18, 2021 08:45 am ET
Bioventus to Expand Operations and Manufacturing in Memphis
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has signed a lease agreement to double its current operations and manufacturing space and relocate from its current facility in suburban...
Nov 15, 2021 07:30 am ET
Bioventus Announces Chief Financial Officer Transition Plan
Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today announced that Greg Anglum is transitioning from his role as Senior Vice President and Chief Financial Officer (CFO) to pursue...
Nov 09, 2021 07:00 am ET
Bioventus Reports Third Quarter Results; Updates Full-Year 2021 Financial Guidance
Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for three and nine months ended October 2, 2021. Q3 Financial Summary & Recent Highlights: Net Sales...
Nov 01, 2021 08:30 am ET
Sharon Klugewicz Joins Bioventus as Senior Vice President, Quality and Regulatory Affairs
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has appointed Sharon Klugewicz as Senior Vice President, Quality and Regulatory Affairs. In this role, she will be responsible for all...
Oct 29, 2021 08:25 am ET
Bioventus Completes the Acquisition of Misonix
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has completed the acquisition of Misonix, Inc. (“Misonix”), a provider of minimally invasive therapeutic ultrasonic technologies and...
Oct 27, 2021 04:15 pm ET
Bioventus to Release Third Quarter of Fiscal Year 2021 Financial Results on November 9, 2021
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that third quarter of fiscal year 2021 financial results will be released before the market opens on Tuesday, November...
Oct 26, 2021 04:15 pm ET
Bioventus and Misonix Stockholders Approve the Acquisition of Misonix by Bioventus
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, and Misonix, Inc. (Nasdaq: MSON) (“Misonix”), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative...
Oct 18, 2021 08:00 am ET
BIOVENTUS INC. and MISONIX, INC. Announce Election Deadline of 5:00 p.m. New York City Time, on October 25, 2021 for Misonix Stockholders to Elect Form of Merger Consideration
Bioventus Inc. (Nasdaq: BVS) and Misonix, Inc. (Nasdaq: MSON) (“Misonix”), today announced an election deadline of 5:00 p.m., New York City Time, on October 25, 2021 (the “Election Deadline”) for stockholders of Misonix to elect the form of...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.